The 340B Drug Pricing Program requires drug manufacturers to provide outpatient drugs to eligible health care organizations/covered entities at significantly reduced prices.
The 340B Program enables covered entities to stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
Eligible health care organizations/covered entities are defined in statute and include HRSA-supported health centers and look-alikes, Ryan White clinics and State AIDS Drug Assistance programs, Medicare/Medicaid Disproportionate Share Hospitals, children’s hospitals, and other safety net providers. See the full list of eligible organizations/covered entities.
To participate in the 340B Program, eligible organizations/covered entities must register and be enrolled with the 340B program and comply with all 340B Program requirements. Once enrolled, covered entities are assigned a 340B identification number that vendors verify before allowing an organization to purchase 340B discounted drugs.
New registrations are accepted October 1-15, January 1-15, April 1-15 and July 1-15.
FY13 Program Audit Results 03/21/2014
Bayer Limited Distribution System for Betaseron (PDF - 66 KB) 01/2014
ADAP Rebate Letter (PDF - 238 KB) 01/31/2014
Program Audit Results updated 01/04/2014
Merck Pharmaceutical notice of 340B ceiling price recalculation for Organon products (PDF - 170 KB) 12/23/2013
Policy Release Updates
340B Glossary of Terms (PDF - 299 KB)